海思科：HSK47388片新适应症药物临床试验获批

Core Viewpoint - The company received approval from the National Medical Products Administration for clinical trials of HSK47388 tablets, which are intended for the treatment of autoimmune diseases [1] Group 1 - The clinical trial approval was granted for HSK47388 tablets, which are a self-developed oral medication with high selectivity and potency [1] - The application represents a new indication for HSK47388 in the field of autoimmune diseases, potentially providing a new treatment option for patients [1] - The approval was based on the compliance of HSK47388 with drug registration requirements as of June 2025 [1]